| Assessment Status |
Rapid Review Complete |
| HTA ID |
26002 |
| Drug |
Budesonide targeted-release formulation (TRF) |
| Brand |
Kinpeygo® |
| Indication |
Budesonide TRF (Kinpeygo®) is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥ 1.0g/day (or urine protein-to-creatinine ratio ≥ 0.8 g/g). |
| Rapid review commissioned |
09/01/2026 |
| Rapid review completed |
09/02/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of TRF-budesonide compared with the current standard of care. |
